Associated Papers
Family Matters: Dissecting the Impact of Family Medical History, APOL1 Genotype, and Sociodemographic Factors on CKD Progression in the Chronic Renal Insufficiency Cohort (CRIC) Study.
Fischman CJ et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 2026
APOL1 kidney risk variants and outcomes in children with congenital anomalies of the kidney and urinary tract.
Vendrig LM et al.
Pediatric Nephrology (berlin, Germany), 2026
Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis.
Wongboonsin J et al.
Kidney International, 2025
Quantifying APOL1, Human Leukocyte Antigen, and Other Genetic Contributions to Unexplained Kidney Failure.
Sadeghi-Alavijeh O et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 2025
APOL1 G1/G2 Variants Associated With CKD in Afro-Brazilians.
Souza CMB et al.
Kidney International Reports, 2025
APOL1 testing in clinical practice and opportunities for new therapies.
Lee T et al.
Current Opinion in Nephrology and Hypertension, 2025
A Human Glomerular Disease Atlas defines the APOL1-JAK-STAT feed forward loop in focal segmental glomerulosclerosis.
McCown PJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Using Large Genomic Biobanks to Generate Insights into Genetic Kidney Disease.
Chang AR et al.
Seminars in Nephrology, 2025
APOL1 Mediated Kidney Disease: A Review and Look Toward the Future.
Srinivasan V et al.
Kidney Medicine, 2025
Apolipoprotein L1 (APOL1): Consideration of Molecular Evolution, Interaction with APOL3, and Impact of Splice Isoforms Advances Understanding of Cellular and Molecular Mechanisms of Cell Injury.
Khalaila R et al.
Cells, 2025
APOL1-associated kidney disease: modulators of the genotype-phenotype relationship.
Pollak MR et al.
Current Opinion in Nephrology and Hypertension, 2025
Platform-dependent effects of genetic variants on plasma APOL1.
Wang QS et al.
Biorxiv : the Preprint Server for Biology, 2025
Epigenetic associations with kidney disease in individuals of African ancestry with APOL1 high-risk genotypes and HIV.
Hung RKY et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2025
The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event.
Simeone CA et al.
G3 (bethesda, Md.), 2025
Multiethnic prevalence of the APOL1 G1 and G2 variants among the Israeli dialysis population.
Ben-Ruby D et al.
Clinical Kidney Journal, 2025
Implementation of a Kidney Genetic Service Into the Diagnostic Pathway for Patients With Chronic Kidney Disease in Canada.
Schott C et al.
Kidney International Reports, 2025
APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans.
Gbadegesin RA et al.
The New England Journal of Medicine, 2025
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease.
Zimmerman B et al.
Nature Communications, 2025
Apolipoprotein-L1 (APOL1): From Sleeping Sickness to Kidney Disease.
Pays E
Cells, 2024
Protein-truncating variant in APOL3 increases chronic kidney disease risk in epistasis with APOL1 risk alleles.
Zhang DY et al.
Jci Insight, 2024
Variant upon variant: kidney-disease risk associated with APOL1 G2 genetic variants is abrogated by the APOL1 p.N264K variant.
Madhavan SM et al.
Kidney International, 2024
APOL1 nephropathy - a population genetics success story.
Tabachnikov O et al.
Current Opinion in Nephrology and Hypertension, 2024
The Mechanism of Kidney Disease due to APOL1 Risk Variants: Involvement of Two Distinct Processes.
Pays E
Journal of the American Society of Nephrology : Jasn, 2024
Diagnostic Yield of APOL1 p.N264K Variant Screening in Daily Practice.
Narjoz C et al.
Kidney International Reports, 2024
Phenome-wide analysis reveals epistatic associations between APOL1 variants and chronic kidney disease and multiple other disorders.
Adamson WE et al.
Ebiomedicine, 2024
Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.
Gupta N et al.
Scientific Reports, 2024
Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.
Gupta Y et al.
Nature Communications, 2023
Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.
Hung AM et al.
Journal of the American Society of Nephrology : Jasn, 2023
Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.
Gupta Y et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain.
Schaub C et al.
The Journal of Biological Chemistry, 2020
Promises and pitfalls of whole-exome sequencing exemplified by a nephrotic syndrome family.
Guaragna MS et al.
Molecular Genetics and Genomics : Mgg, 2020
Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.
Lannon H et al.
Kidney International, 2019
Apolipoprotein L1 Variant Associated with Increased Susceptibility to Trypanosome Infection.
Cuypers B et al.
Mbio, 2016
Sequencing rare and common APOL1 coding variants to determine kidney disease risk.
Limou S et al.
Kidney International, 2015
Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations.
Ko WY et al.
American Journal of Human Genetics, 2013
Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
Hu CA et al.
Febs Letters, 2012
Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children.
Ray PE et al.
Future Virology, 2011
APOL1 Genotyping Is Incomplete without Testing for the Protective M1 Modifier p.N264K Variant.
Gbadegesin R et al.
Glomerular Diseases, 0